Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor, Hepatitis C Virus NS5A Inhibitor, Hepatitis C Virus NS3/4A Protease Inhibitor
WHO Essential Medicine EML section: Pangenotypic direct-acting antiviral combinations
This is information only, not a prescription. Talk to a doctor or pharmacist before taking any medicine. For an overdose or poisoning, call 102.
RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with VOSEVI.
Sofosbuvir is used to treat adult patients with chronic hepatitis C virus (HCV) infection. It is indicated for patients with genotype 1, 2, 3, 4, 5, or 6 infection who have previously been treated with an HCV regimen containing an NS5A inhibitor. It also targets genotype 1a or 3 infection with an HCV regimen containing sofosbuvir without an NS5A inhibitor. Sofosbuvir belongs to the class of drugs known as Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitors, NS5A Inhibitors, and NS3/4A Protease Inhibitors. Common side effects include serious symptoms such as symptomatic bradycardia when used with amiodarone, and the most common adverse reactions observed are headache, fatigue, diarrhea, and nausea. It is contraindicated with rifampin and should not be used during pregnancy or breastfeeding.
Sources: FDA SPL label (openFDA/DailyMed); RxNorm (NLM) · Reference · Reference · Reference
Nepal brand names not included: no licence-safe source.
is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have: genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor. genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor.
The following serious adverse reactions are described below and elsewhere in labeling: Serious Symptomatic Bradycardia When Coadministered with Amiodarone. The most common adverse reactions (incidence greater than or equal to 10%, all grades) observed with treatment with VOSEVI for 12 weeks were headache, fatigue, diarrhea, and nausea.
is contraindicated with rifampin. Coadministration with rifampin.
Pregnancy (label summary): Risk Summary No adequate human data are available to establish whether or not VOSEVI poses a risk to pregnancy outcomes.
For a suspected overdose or poisoning, call 102 now and go to the nearest emergency hospital.
Call 102What is Sofosbuvir used for?
is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have: genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor.
What are the side effects of Sofosbuvir?
The following serious adverse reactions are described below and elsewhere in labeling: Serious Symptomatic Bradycardia When Coadministered with Amiodarone. The most common adverse reactions (incidence greater than or equal to 10%, all grades) observed with treatment with VOSEVI for 12 weeks were headache, fatigue,...
Who should not take Sofosbuvir?
is contraindicated with rifampin. Coadministration with rifampin.
Does Sofosbuvir have a boxed warning?
RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with VOSEVI.
Can I take Sofosbuvir in pregnancy or while breastfeeding?
Pregnancy (label summary): Risk Summary No adequate human data are available to establish whether or not VOSEVI poses a risk to pregnancy outcomes.
What is the dose of Sofosbuvir?
Not provided here. Ask a doctor or pharmacist.
What is Sofosbuvir?
Sofosbuvir is used for: is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have: genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor. ge…
Sources: FDA SPL label (openFDA/DailyMed); RxNorm (NLM) · Reference · Reference · Reference
US FDA DailyMed; NLM RxNorm